BELLUS Health Inc.
  • Financial Services
  • Healthcare Facility
  • Medical/ Pharmaceuticals

Organization Profile

BELLUS Health is developing a portfolio of drugs for rare diseases including Kiacta in Phase III for AA Amyloidosis and clinical stage Shigamabs for STEC-related Hemolytic Uremic Syndrome (sHUS). The Company's lead program KIACTA™ is currently in a Phase III Confirmatory Study for the treatment of AA amyloidosis, an orphan indication resulting in renal dysfunction that often rapidly leads to dialysis and death. KIACTA™ is partnered with global private equity firm Auven Therapeutics.

Contact Information

Investor Contact
Adam Peeler - TMX Equicom
Tel: (416) 815-0700 ext. 225